Angioneurotic edema attributed to the use of losartan.
- 12 October 1998
- journal article
- case report
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 158 (18), 2063-2065
- https://doi.org/10.1001/archinte.158.18.2063
Abstract
Angioedema is a well-known adverse effect of angiotensin-converting enzyme inhibitors. The bradykinin accumulation as a result of the decreased degradation of bradykinin is thought to be the causal mechanism. Angiotensin II antagonists seem to have no effect on the degradation of bradykinin. Therefore, it was expected that angioedema would not occur during treatment with losartan potassium, the first orally active angiotensin II antagonist.Keywords
This publication has 9 references indexed in Scilit:
- A Risk-Benefit Assessment of Losartan Potassium in the Treatment of HypertensionDrug Safety, 1997
- Accupril- and Cozaar-induced angioedema in the same patientJournal of Allergy and Clinical Immunology, 1996
- Angioedema Induced by the Angiotensin II Blocker LosartanNew England Journal of Medicine, 1995
- Angiotensin receptor antagonists: focus on losartanThe Lancet, 1995
- Comparison of Angiotensin-Converting Enzyme Inhibition with Angiotensin II Receptor Antagonism in the Human ForearmJournal of Cardiovascular Pharmacology, 1993
- Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor TherapyAnnals of Internal Medicine, 1992
- Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors.BMJ, 1992
- Possible contraindication of angiotensin converting enzyme inhibitors in patients with hereditary angioedemaThe American Journal of Medicine, 1990
- Effect of vasoactive peptides on prostacyclin synthesis in manBritish Journal of Pharmacology, 1986